| GTO ID | GTC2395 |
| Trial ID |
NCT04452994
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-DC cell|CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Recruitment status | No Longer Available |
| Title | Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma |
| Year | 2020 |
| Country | United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | CR108848 |